Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2018.
    • 27 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 01 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top